When the topic of affordability of healthcare comes up, people usually mean the price of healthcare, but there is a difference, said Tomas Philipson, PhD, of the University of Chicago, at the ISPOR Annual Meeting.
When the topic of affordability of healthcare comes up, people usually mean the price of healthcare, but there is a difference, said Tomas Philipson, PhD, of the University of Chicago, at the ISPOR Annual Meeting.
Another common misconception is the claim that the cost of research and development of drugs is driving the high prices. In reality, he explained, the cost of a drug is simply determined by demand and the question of how much can a company can raise prices before customers go away. So if a drug had massive side effects, it wouldn’t matter how much money a company had sunk into the treatment’s R&D because no one would be interested in paying that much for a drug with so many side effects.
“The problem with that is you can’t assess drugs in isolation,” Philipson said. “You have to think of a development portfolio."
However, Dan Ollendorf, PhD, of the Institute for Clinical and Economic Review, argued that the issue is not just high prices. The issue is that prices are continuing to increase after a product launches.
“There are certainly drugs that have revolutionized the care of certain conditions,” he said. “But we still have got to figure out how to fund them.”
He added though that the magnitude of net health benefit cannot be overlooked. For instance, if someone developed a cure for Alzheimer’s disease, then “all bets are off.” So what can be done? While there are bills in state legislatures trying to force pharmaceutical companies into being more transparent, Ollendorf believes that to be a fool’s errand. But there are other possible solutions, such as alternative financing, risk-sharing agreements, prioritized access to treatments, disinvestment, and price negotiations.
During the discussion period, it was clear that Ollendorf and Philipson were in disagreement about the level of competition in the market.
“I would argue that if we were in a truly competitors market I wouldn’t have a job,” Ollendorf said. “We wouldn’t have the situation where 2 similar products come on to the market within weeks of each other at the same price.”
However, Philipson pointed out that there is nothing forcing insurance companies to pay the prices set by companies. Perhaps, among public payers there is a role for a third party to advice on what prices should be paid, but in the private market competition and demand should prevail.
“There’s a big mismatch between value frameworks and patient behaviors,” Philipson said. “Patients are willing to go bankrupt for these therapies. How many products are you willing to go bankrupt for?”
The fact that patients are willing to pay the prices and go bankrupt is their way of saying that the treatment is valuable. Philipson said this shows that we haven’t figured out how to measure value properly.
Ollendorf countered by saying that houses and cars are expensive, but people have the option to not by them.
“If you have cancer and are dying, you will pay whatever you can to survive,” he said.
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More